NASDAQ:BRKR - Nasdaq - US1167941087 - Common Stock - Currency: USD
Scientific instrument company Bruker (NASDAQ:BRKR). reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 14.6% year on year to $979.6 million. On the other hand, the company’s full-year revenue guidance of $3.51 billion at the midpoint came in 1.8% below analysts’ estimates. Its non-GAAP profit of $0.76 per share was 3.2% above analysts’ consensus estimates.
Scientific instrument company Bruker (NASDAQ:BRKR). reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 14.6% year on year to $979.6 million. On the other hand, the company’s full-year revenue guidance of $3.51 billion at the midpoint came in 1.8% below analysts’ estimates. Its non-GAAP profit of $0.76 per share was 3.2% above analysts’ consensus estimates.
/PRNewswire/ -- Today, IonOpticks, a world leading provider of chromatography solutions, and Biognosys, a global leader in mass spectrometry-based proteomics...
Scientific instrument company Bruker (NASDAQ:BRKR). will be reporting results tomorrow before market hours. Here’s what investors should know.
Scientific instrument company Bruker (NASDAQ:BRKR). will be reporting results tomorrow before market hours. Here’s what investors should know.
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S....
Mentions: TXG